You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Immunol., 13 March 2024

Sec. Inflammation

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1390698

Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19

  • 1. Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan

  • 2. Department of Enzymes Chemistry and Biochemistry, Palladin Institute of Biochemistry of the National Academy of Science of Ukraine, Kyiv, Ukraine

  • 3. Institute of Computing, Federal University of Bahia, Salvador, Bahia, Brazil

  • 4. An-Najah Center for Cancer and Stem Cell Research, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine

  • 5. Division of Clinical Precision Research Platform, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan

  • 6. Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan

  • 7. Center for Genome and Regenerative Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan

  • 8. Department of Hematology/Oncology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan

Article metrics

View details

1

Citations

1,2k

Views

565

Downloads

In the published article, there was an error in the author list, and author Yousef Salama, along with their affiliation, was erroneously excluded. The corrected author list and affiliations appear below.

Tetiana Yatsenko1,2, Ricardo Rios3, Tatiane Nogueira3, Yousef Salama4, Satoshi Takahashi5, Yoko Tabe1, Toshio Naito1, Kazuhisa Takahashi1,6, Koichi Hattori 7,8* and Beate Heissig 1*

1Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan

2Department of Enzymes Chemistry and Biochemistry, Palladin Institute of Biochemistry of the National Academy of Science of Ukraine, Kyiv, Ukraine

3Institute of Computing, Federal University of Bahia, Salvador, Bahia, Brazil

4 An-Najah Center for Cancer and Stem Cell Research, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine;

5Division of Clinical Precision Research Platform, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan

6Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan

7Center for Genome and Regenerative Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan

8Department of Hematology/Oncology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

In the published article, there was an error in the Author Contribution section. Due to the fact author Yousef Salama was erroneously excluded, their contributions were not included in this section. The corrected Author Contribution section appears below.

Author contributions

BH: Conceptualization, Funding acquisition, Writing – original draft. RR: Formal analysis, Methodology, Software, Writing – review & editing. TNo: Formal analysis, Methodology, Software, Writing – review & editing. YS: Data curation, Writing – review & editing. ST: Funding acquisition, Writing – review & editing. YT: Resources, Writing – review & editing. TNa: Resources, Writing – review & editing. KT: Resources, Writing – review & editing. KH: Conceptualization, Funding acquisition, Writing – review & editing. TY: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – review & editing, Writing – original draft.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

COVID-19, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, interleukin-6, fibrinolysis, thrombosis, C-reactive protein, respiratory distress syndrome

Citation

Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Tabe Y, Naito T, Takahashi K, Hattori K and Heissig B (2024) Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19. Front. Immunol. 15:1390698. doi: 10.3389/fimmu.2024.1390698

Received

23 February 2024

Accepted

01 March 2024

Published

13 March 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2024

Updates

Copyright

*Correspondence: Beate Heissig, ; Koichi Hattori,

†ORCID: Koichi Hattori, orcid.org/0000000313800704; Beate Heissig, orcid.org/0000-0002-0348-5934

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics